Ocular Therapeutix, Inc. $OCUL Shares Sold by Deltec Asset Management LLC

Deltec Asset Management LLC lessened its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 5.9% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 2,340,620 shares of the biopharmaceutical company’s stock after selling 147,314 shares during the quarter. Ocular Therapeutix comprises 3.6% of Deltec Asset Management LLC’s holdings, making the stock its 6th biggest position. Deltec Asset Management LLC’s holdings in Ocular Therapeutix were worth $19,825,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of OCUL. Steward Partners Investment Advisory LLC lifted its stake in shares of Ocular Therapeutix by 124.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,242 shares during the period. Rockefeller Capital Management L.P. acquired a new position in shares of Ocular Therapeutix during the fourth quarter valued at approximately $31,000. Hilton Head Capital Partners LLC raised its holdings in Ocular Therapeutix by 30.4% during the first quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,053 shares in the last quarter. Atlas Capital Advisors Inc. bought a new stake in Ocular Therapeutix during the fourth quarter worth approximately $61,000. Finally, KBC Group NV acquired a new stake in Ocular Therapeutix in the fourth quarter worth approximately $78,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Stock Performance

Shares of Ocular Therapeutix stock opened at $9.47 on Thursday. Ocular Therapeutix, Inc. has a 12 month low of $6.23 and a 12 month high of $16.44. The company has a quick ratio of 14.73, a current ratio of 14.81 and a debt-to-equity ratio of 0.12. The stock has a market cap of $2.07 billion, a PE ratio of -6.49 and a beta of 0.88. The business has a fifty day simple moving average of $9.11 and a 200-day simple moving average of $9.68.

Analysts Set New Price Targets

A number of brokerages have issued reports on OCUL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Tuesday, April 21st. Royal Bank Of Canada reissued an “outperform” rating and issued a $30.00 price objective on shares of Ocular Therapeutix in a research note on Wednesday, May 6th. Robert W. Baird upped their price objective on Ocular Therapeutix from $24.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Chardan Capital raised their target price on Ocular Therapeutix from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price (up from $21.00) on shares of Ocular Therapeutix in a report on Thursday, June 18th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $25.11.

Insider Buying and Selling

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,156 shares of Ocular Therapeutix stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total transaction of $173,479.20. Following the transaction, the insider owned 2,597,170 shares of the company’s stock, valued at $21,296,794. The trade was a 0.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 28,999 shares of company stock worth $237,792. Company insiders own 3.10% of the company’s stock.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.